{"filing":{"accession_number":"0001723128-26-000025","cik":"0001723128","ticker":"AMRX","company_name":"Amneal Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"amrx-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-20260730.htm"},"events":[{"id":21938,"run_id":19808,"accession_number":"0001723128-26-000025","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Amneal Pharmaceuticals disclosed Q2 2026 financial results with net revenue of $796 million, GAAP net income of $58 million, and diluted EPS of $0.18, along with raised full-year 2026 guidance. The disclosure includes a conference call to discuss the results.","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21718,"accession_number":"0001723128-26-000025","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Amneal Pharmaceuticals. The Item 2.02 filing announces net revenue of $796 million, GAAP net income of $58 million, and diluted EPS of $0.18, along with raised full-year 2026 guidance. The press release (Exhibit 99.1) is the primary disclosure vehicle, which is typical for earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:16:39.838776+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21719,"accession_number":"0001723128-26-000025","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 7.01 discloses a conference call to discuss Amneal's Q2 2026 financial results. The supplemental exhibit (EX-99.1) contains the full earnings release announcing Q2 2026 net revenue of $796 million, GAAP net income of $58 million, diluted EPS of $0.18, and raised full-year 2026 guidance. This is a standard earnings release disclosure material to investors assessing the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:16:39.838776+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21718,"accession_number":"0001723128-26-000025","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Amneal Pharmaceuticals. The Item 2.02 filing announces net revenue of $796 million, GAAP net income of $58 million, and diluted EPS of $0.18, along with raised full-year 2026 guidance. The press release (Exhibit 99.1) is the primary disclosure vehicle, which is typical for earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:16:39.838776+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-07-30"},{"id":21719,"accession_number":"0001723128-26-000025","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 7.01 discloses a conference call to discuss Amneal's Q2 2026 financial results. The supplemental exhibit (EX-99.1) contains the full earnings release announcing Q2 2026 net revenue of $796 million, GAAP net income of $58 million, diluted EPS of $0.18, and raised full-year 2026 guidance. This is a standard earnings release disclosure material to investors assessing the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:16:39.838776+00:00","company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","filing_date":"2026-07-30"}]}